Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The trial assess the maximum tolerated dose of a single-dose of Brentuximab Vedotin added to
standard BeEAM chemotherapy (comprising Bendamustin, Etoposide, Cyclophosphamide and
Melphalan) before autologous stem cell transplantation in CD30+ malignant lymphomas.